Skip to main content

Table 1 Chromosomal translocation and fusion proteins in solid tumors involving ALK gene

From: Novel ALK inhibitors in clinical use and development

Disease Chromosomal rearrangement Fusion protein Frequency (%) Reference
NSCLC inv(2)(p21;p23) EML4-ALK 2-5 [59,64,65]
  t(2;3)(p23;q21) TFG-ALK 2 [65]
  t(2;10)(p23;p11) KIF5B-ALK <1 [53,57]
  t(2;14)(p23;q32) KLC1-ALK <5 [55]
  t(2;9)(p23;q31) PTPN3-ALK ND [50]
IMT t(1;2)(q25;p23) TPM3-ALK 0.5 [24]
  t(2;19)(p23;p13) TPM4-ALK <5 [24]
  t(2;17)(p23;q23) CLTC-ALK <5 [40,42,43]
  inv(2)(p23;q35) ALK-ATIC <5 [32]
  t(2;11;2)(p23;p15;q31) CARS-ALK <5 [34,35]
  t(2;2)(p23;q13) RANBP2-ALK <5 [36]
  inv(2)(p23;p15;q31) RANBP2-ALK <5 [38]
  t(2;4)(p23;q21) SEC31L1-ALK <5 [52]
BC inv(2)(p21;p23) EML4-ALK <5 [64]
CRC inv(2)(p21;p23) EML4-ALK <5 [64]
  t(2;2)(p23.3) C2orf44-ALK <5 [51]
ESCC t(2;19)(p23;p13) TPM4-ALK ND [27,28]
RCC t(2;10)(p23;q22) VCL-ALK ND [47]
  t(1;2)(q25;p23) TPM3–ALK ND [23]
  inv(2)(p21;p23) EML4–ALK ND [23]
  1. NSCLC; non small cell lung cancer, IMT; inflammatory myofibroblastic tumor, BC; breast cancer, CRC; colorectal cancer, ESCC; esophageal squamous cell carcinoma, RCC; renal cell carcinoma, ND; not determined.